Paricalcitol
Capsule · trading as Zemplar
To Be Discontinued
FDA shortage record
- Substance
- Paricalcitol
- Brand name
- Zemplar
- Manufacturer
- AbbVie Inc.
- Dosage form
- Capsule
- Presentation
- Zemplar, Capsule, 1 ug (NDC 0074-9036-30)
- Route(s)
- ORAL
- Therapeutic category
- Endocrinology/Metabolism
- Package NDC
0074-9036-30- Initially posted
- 10/07/2025
- Discontinued
- 10/07/2025
- Current FDA status
- To Be Discontinued
Reason and context
Discontinuation of the manufacture of the drug
Manufacturer contact
Per the FDA record, the manufacturer's contact for supply inquiries is 800-633-9110.
If you're affected by this shortage
- Talk to your prescribing clinician or pharmacist about therapeutic alternatives. Do not switch medications on your own.
- Ask your pharmacy to check supply across multiple wholesalers and other branches.
- Check current pharmacy pricing and availability via GoodRx (affiliate link).
- Report a continuing supply problem to FDA via the FDA Drug Shortages contact form.
Sources
- FDA Drug Shortages database, accessed via the openFDA Drug Shortages API.
- FDA Structured Product Label (SPL set ID
1b27c026-2d60-47b4-2a9c-ded1818f21b5). - FDA UNII identifier:
6702D36OG5. - See the Drug Shortage Tracker methodology for sourcing, update cadence, normalization rules, and limits.
Important
This page reproduces publicly available FDA shortage data for informational purposes only. It is not medical advice and does not establish a clinician-patient relationship. Shortage status changes frequently; verify directly with your pharmacist or the FDA Drug Shortages site before making any treatment decision.